Paradigm shift in the pharmacological management of periodontal diseases

Frontiers of Oral Biology

Volumn 15, Issue , 2012, Pages 160-176

  Hasturk, Hatice ^a   Kantarci, Alpdogan ^a   Van Dyke, Thomas E ^a  

^a FORSYTH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; ICOSAPENTAENOIC ACID; LIPOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID;

GINGIVITIS; HUMAN; IMMUNOLOGY; INFLAMMATION; NEUTROPHIL; PERIODONTITIS; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; GINGIVITIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOXINS; NEUTROPHILS; PERIODONTITIS;

EID: 84855560497     PISSN: 14202433     EISSN: 16623770     Source Type: Book Series    
DOI: 10.1159/000329678     Document Type: Article

References (112)

1. Socransky SS, Haffajee AD: Periodontal microbial ecology. Periodontol 2000 2005;38:135-187. (Pubitemid 43034326)
2. Haffajee AD, Socransky SS: Microbiology of periodontal diseases: introduction.Periodontol 2000 2005;38:9-12. (Pubitemid 43034320)
3. Keyes PH, Jordan HV: Periodontal lesions in the Syrian hamster. III. Findings related to an infectious and transmissible component. Arch Oral Biol 1964; 9:377-400.
4. Newman MG, Socransky SS, Savitt ED, Propas DA, Crawford A: Studies of the microbiology of periodontosis. J Periodontol 1976;47:373-379.
5. Miller WD: The Micro-Organisms of the Human Mouth. Philadelphia, S.S. White, 1890.
6. Zambon JJ: Periodontal diseases: microbial factors. Ann Periodontol 1996;1:879-925.
7. Jorgensen MG, Slots J: Responsible use of antimicrobials in periodontics. J Calif Dent Assoc 2000; 28:185-193.
8. Hallmon WW, Rees TD: Local anti-infective therapy: mechanical and physical approaches. A systematic review. Ann Periodontol 2003;8:99-114.
9. Loesche WJ: Chemotherapy of dental plaque infections. Oral Sci Rev 1976;9:65-107.
10. Harper DS, Robinson PJ: Correlation of histometric, microbial, and clinical indicators of periodontal disease status before and after root planing. J Clin Periodontol 1987;14:190-196.
11. Magnusson I, Lindhe J, Yoneyama T, Liljenberg B: Recolonization of a subgingival microbiota following scaling in deep pockets. J Clin Periodontol 1984; 11:193-207.
12. Paster BJ, Boches SK, Galvin JL, Ericson RE, Lau CN, Levanos VA, Sahasrabudhe A, Dewhirst FE: Bacterial diversity in human subgingival plaque. J Bacteriol 2001;183:3770-3783. (Pubitemid 32510445)
13. Marsh PD, Moter A, Devine DA: Dental plaque biofilms: communities, conflict and control. Periodontol 2000 2011;55:16-35.
14. Armitage GC, Robertson PB: The biology, prevention, diagnosis and treatment of periodontal diseases: scientific advances in the United States. J Am Dent Assoc 2009;140(suppl 1):36S-43S.
15. Van Dyke TE, Serhan CN: Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res 2003;82:82-90. (Pubitemid 41764116)
16. Kinane DF, Lappin DF: Immune processes in periodontal disease: a review. Ann Periodontol 2002;7: 62-71.
17. Beertsen W, McCulloch CA, Sodek J: The periodontal ligament: a unique, multifunctional connective tissue. Periodontol 2000 1997;13:20-40. (Pubitemid 127579970)
18. Kornman KS, Page RC, Tonetti MS: The host response to the microbial challenge in periodontitis: assembling the players. Periodontol 2000 1997;14: 33-53.
19. Kinane DF, Lowe GD: How periodontal disease may contribute to cardiovascular disease. Periodontol 2000 2000;23:121-126.
20. Pasteur L: On the germ theory. Science 1881;2:420-422.
21. King LS: Dr. Koch's postulates. J Hist Med Allied Sci 1952;7:350-361.
22. Abraham EP: Discovery and development of penicillin. Dent Rec (London) 1946;66:197-200.
23. Harrison JW, Svec TA: The beginning of the end of the antibiotic era? II. Proposed solutions to antibiotic abuse. Quintessence Int 1998;29:223-229. (Pubitemid 128687443)
24. Fischman SL: The history of oral hygiene products: how far have we come in 6000 years? Periodontol 2000 1997;15:7-14.
25. Mandel ID: Why pick on teeth? J Am Dent Assoc 1990;121:129-132.
26. Loe H, Theilade E, Jensen SB: Experimental gingivitis in man. J Periodontol 1965;36:177-187.
27. Socransky SS: Relationship of bacteria to the etiology of periodontal disease. J Dent Res 1970;49:203-222.
28. Lindhe J, Nyman S: The effect of plaque control and surgical pocket elimination on the establishment and maintenance of periodontal health: a longitudinal study of periodontal therapy in cases of advanced disease. J Clin Periodontol 1975;2:67-79.
29. Krayer JW, Leite RS, Kirkwood KL: Non-surgical chemotherapeutic treatment strategies for the management of periodontal diseases. Dent Clin North Am 2010;54:13-33.
30. Ford PJ, Raphael SL, Cullinan MP, Jenkins AJ, West MJ, Seymour GJ: Why should a doctor be interested in oral disease? Expert Rev Cardiovasc Ther 2010;8: 1483-1493.
31. Griffin SO, Barker LK, Griffin PM, Cleveland JL, Kohn W: Oral health needs among adults in the United States with chronic diseases. J Am Dent Assoc 2009;140:1266-1274.
32. Hajishengallis G: Too old to fight? Aging and its toll on innate immunity. Mol Oral Microbiol 2010;25: 25-37.
33. Kao RT, Lee S, Harpenau L: Clinical challenges in diagnosing and monitoring periodontal inflammation. J Calif Dent Assoc 2010;38:263-270.
34. Cotran RS, Kumar V, Collins T: Robbins Pathologic Basis of Disease. Philadelphia, Saunders, 1999.
35. Kumar V, Abbas AK, Fausto N: Robbins and Cotran Pathologic Basis of Disease, ed 7. Philadelphia, Elsevier Saunders, 2005.
36. Wada K, Qiu FH, Stahl GL, Serhan CN: Inosine monophosphate and aspirin-triggered 15-epi-lipoxin A4 act in concert to regulate neutrophil trafficking: additive actions of two new endogenous antiinflammatory mediators. J Hematother Stem Cell Res 2001;10:75-79. (Pubitemid 32233694)
37. Serhan CN, Oliw E: Unorthodox routes to prostanoid formation: new twists in cyclooxygenaseinitiated pathways. J Clin Invest 2001;107: 1481-1489. (Pubitemid 32574630)
38. Van Dyke TE, Zinney W, Winkel K, Taufiq A, Offenbacher S, Arnold RR: Neutrophil function in localized juvenile periodontitis: phagocytosis, superoxide production and specific granule release. J Periodontol 1986;57:703-708.
39. Dongari-Bagtzoglou AI, Ebersole JL: Production of inflammatory mediators and cytokines by human gingival fibroblasts following bacterial challenge. J Periodontal Res 1996;31:90-98.
40. Genco RJ: Host responses in periodontal diseases: current concepts. J Periodontol 1992;63(suppl): 338-355.
41. Page RC, Schroeder HE: Pathogenesis of inflammatory periodontal disease: a summary of current work. Lab Invest 1976;34:235-249.
42. Kantarci A, Oyaizu K, Van Dyke TE: Neutrophilmediated tissue injury in periodontal disease pathogenesis: findings from localized aggressive periodontitis. J Periodontol 2003;74:66-75. (Pubitemid 36181488)
43. Kantarci A, Hasturk H, Van Dyke TE: Hostmediated resolution of inflammation in periodontal diseases. Periodontol 2000 2006;40:144-163.
44. Pouliot M, Clish CB, Petasis NA, Van Dyke TE, Serhan CN: Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 2000;39:4761-4768. (Pubitemid 30225341)
45. Offenbacher S, Odle BM, Gray RC, Van Dyke TE: Crevicular fluid prostaglandin E levels as a measure of the periodontal disease status of adult and juvenile periodontitis patients. J Periodontal Res 1984; 19:1-13.
46. Kelley DS: Modulation of human immune and inflammatory responses by dietary fatty acids. Nutrition 2001;17:669-673. (Pubitemid 32633805)
47. Benito P, Nelson GJ, Kelley DS, Bartolini G, Schmidt PC, Simon V: The effect of conjugated linoleic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Lipids 2001;36: 221-227. (Pubitemid 32290916)
48. O'Banion MK, Winn VD, Young DA: cDNA cloning and functional activity of a glucocorticoidregulated inflammatory cyclooxygenase. Proc Natl Acad Sci U S A 1992;89:4888-4892.
49. O'Banion MK: Cyclooxygenase-2:molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999;13:45-82.
50. Samuelsson B: The leukotrienes: an introduction. Adv Prostaglandin Thromboxane Leukot Res 1982; 9:1-17.
51. Samuelsson B: An elucidation of the arachidonic acid cascade: discovery of prostaglandins, thromboxane and leukotrienes. Drugs 1987;33(suppl 1): 2-9. (Pubitemid 17070100)
52. Serhan CN, Drazen JM: Antiinflammatory potential of lipoxygenase-derived eicosanoids: a molecular switch at 5 and 15 positions? J Clin Invest 1997; 99:1147-1148. (Pubitemid 27147950)
53. Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871-1875. (Pubitemid 33101574)
54. Bandeira-Melo C, Bozza PT, Weller PF: The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol 2002;109:393-400. (Pubitemid 34234186)
55. Vane J, Botting R: Inflammation and the mechanism of action of anti-inflammatory drugs. Faseb J 1987;1: 89-96. (Pubitemid 18057324)
56. Vane JR, Botting RM: Mechanism of action of antiinflammatory drugs. Adv Exp Med Biol 1997;433: 131-138.
57. Vane JR, Botting RM: Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:2S-8S, discussion 21S-22S. (Pubitemid 28186987)
58. Flower RJ: Studies on the mechanism of action of anti-inflammatory drugs: a paper in honour of John Vane. Thromb Res 2003;110:259-263. (Pubitemid 37329822)
59. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN: Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237:1171-1176. (Pubitemid 17131222)
60. Drazen JM, Israel E, O'Byrne PM: Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206. (Pubitemid 29063217)
61. Jackson LM, Hawkey CJ: COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages? Drugs 2000;59:1207-1216. (Pubitemid 30410139)
62. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A: Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163: 481-486. (Pubitemid 36241027)
63. Mengle-Gaw LJ, Schwartz BD: Cyclooxygenase-2 inhibitors: promise or peril? Mediators Inflamm 2002;11:275-286. (Pubitemid 35335217)
64. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K: Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000;192:1197-1204.
65. Serhan CN: Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 2002;68-69: 433-455. (Pubitemid 35247413)
66. Serhan CN, Fiore S, Levy BD: Cell-cell interactions in lipoxin generation and characterization of lipoxin A4 receptors. Ann N Y Acad Sci 1994;744:166-180. (Pubitemid 26005821)
67. Badr KF, DeBoer DK, Schwartzberg M, Serhan CN: Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor. Proc Natl Acad Sci U S A 1989;86:3438-3442. (Pubitemid 19129626)
68. Lee TH, Lympany P, Crea AE, Spur BW: Inhibition of leukotriene B4-induced neutrophil migration by lipoxin A4:structure-function relationships. Biochem Biophys Res Commun 1991;180:1416-1421.
69. Serhan CN, Romano M: Lipoxin biosynthesis and actions: role of the human platelet LX-synthase. J Lipid Mediat Cell Signal 1995;12:293-306.
70. Serhan CN, Clish CB: Aspirin triggered lipid mediators: novel inhibitors of leucocyte trafficking. Thorax 2000;55(suppl 2):S10-S12.
71. Serhan CN: A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochem Cell Biol 2004;122:305-321. (Pubitemid 39506589)
72. Claria J, Serhan CN: Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A 1995;92:9475-9479.
73. Birnbaum Y, Ye Y, Lin Y, Freeberg SY, Huang MH, Perez-Polo JR, Uretsky BF: Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. Prostaglandins Other Lipid Mediat 2007;83:89-98. (Pubitemid 46151755)
74. Fiore S, Serhan CN: Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction. Biochemistry 1995;34:16678-16686.
75. Serhan CN, Sheppard KA: Lipoxin formation during human neutrophil-platelet interactions: evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J Clin Invest 1990; 85:772-780. (Pubitemid 20087480)
76. Serhan CN, Maddox JF, Petasis NA, Akritopoulou-Zanze I, Papayianni A, Brady HR, Colgan SP, Madara JL: Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995;34:14609-14615. (Pubitemid 3000720)
77. Levy BD, Drazen JM, Serhan CN: Agonist-induced lipoxin A4 generation in vitro and in aspirinsensitive asthmatics: detection by a novel lipoxin A4-ELISA. Adv Exp Med Biol 1997;400B:611-615.
78. Reddy BS, Rao CV, Seibert K: Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56:4566-4569. (Pubitemid 26338047)
79. DuBois RN, Giardiello FM, Smalley WE: Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 1996;25:773-791. (Pubitemid 27022915)
80. Brady HR, Serhan CN: Lipoxins: putative braking signals in host defense, inflammation and hypersensitivity. Curr Opin Nephrol Hypertens 1996;5: 20-27.
81. Serhan CN: Eicosanoids in leukocyte function. Curr Opin Hematol 1994;1:69-77.
82. Serhan CN: Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim Biophys Acta 1994;1212:1-25. (Pubitemid 24123884)
83. Serhan CN, Fiore S: Lipoxin recognition sites of human neutrophils. Adv Prostaglandin Thromboxane Leukot Res 1994;22:317-326.
84. Nathan C: Points of control in inflammation. Nature 2002;420:846-852. (Pubitemid 36019637)
85. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN: Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001;2:612-619. (Pubitemid 32677628)
86. Levy BD, Lukacs NW, Berlin AA, Schmidt B, Guilford WJ, Serhan CN, Parkinson JF: Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. Faseb J 2007;21:3877-3884. (Pubitemid 350232345)
87. Bannenberg G, Moussignac RL, Gronert K, Devchand PR, Schmidt BA, Guilford WJ, Bauman JG, Subramanyam B, Perez HD, Parkinson JF, Serhan CN: Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol 2004;143:43-52. (Pubitemid 39280023)
88. O'Meara YM, Brady HR: Lipoxins, leukocyte recruitment and the resolution phase of acute glomerulonephritis. Kidney Int Suppl 1997;58:S56-S61.
89. Ye XH, Wu Y, Guo PP, Wang J, Yuan SY, Shang Y, Yao SL: Lipoxin A4 analogue protects brain and reduces inflammation in a rat model of focal cerebral ischemia reperfusion. Brain Res 2010;1323:174-183.
90. Papayianni A, Serhan CN, Phillips ML, Rennke HG, Brady HR: Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int 1995;47:1295-1302.
91. Brezinski DA, Nesto RW, Serhan CN: Angioplasty triggers intracoronary leukotrienes and lipoxin A4: impact of aspirin therapy. Circulation 1992;86:56-63.
92. Stenke L, Reizenstein P, Lindgren JA: Leukotrienes and lipoxins -new potential performers in the regulation of human myelopoiesis. Leuk Res 1994;18: 727-732. (Pubitemid 24302098)
93. Sanak M, Levy BD, Clish CB, Chiang N, Gronert K, Mastalerz L, Serhan CN, Szczeklik A: Aspirintolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000;16: 44-49. (Pubitemid 30480126)
94. Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, Behbehani B, Colgan SP, Stahl GL, Merched A, Petasis NA, Chan L, Van Dyke TE: Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 2003; 171:6856-6865. (Pubitemid 37532121)
95. Calder PC: n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond) 2004;107:1-11. (Pubitemid 38932191)
96. Rahman MM, Bhattacharya A, Fernandes G: Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid. J Cell Physiol 2008;214:201-209. (Pubitemid 350225482)
97. Eickmeier O, Hilberath JN, Zielen S, Haworth O: Pro-resolving lipid mediators in inflammatory lung diseases. Pneumologie 2011;65:149-158.
98. Calder PC: Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 2008;52:885-897.
99. Calder PC, Zurier RB: Polyunsaturated fatty acids and rheumatoid arthritis. Curr Opin Clin Nutr Metab Care 2001;4:115-121. (Pubitemid 34755453)
100. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL: Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196:1025-1037. (Pubitemid 35231761)
101. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG: A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005;115:2774-2783. (Pubitemid 41434404)
102. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN: Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells: autacoids in anti-inflammation. J Biol Chem 2003;278:14677-14687. (Pubitemid 36799790)
103. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, Hardy M, Gimenez JM, Chiang N, Serhan CN, Bazan NG: Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003;278:43807-43817. (Pubitemid 37346009)
104. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG: Neuroprotectin D1: a docosahexaenoic acidderived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A 2004;101:8491-8496. (Pubitemid 38736602)
105. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN: Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 2007;178:3912-3917. (Pubitemid 46417661)
106. Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE: RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. Faseb J 2006;20:401-403. (Pubitemid 46671185)
107. Hudert CA, Weylandt KH, Lu Y, Wang J, Hong S, Dignass A, Serhan CN, Kang JX: Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A 2006; 103:11276-11281. (Pubitemid 44156509)
108. Schwab JM, Chiang N, Arita M, Serhan CN: Resolvin E1 and protectin D1 activate inflammationresolution programmes. Nature 2007;447:869-874. (Pubitemid 46920139)
109. Serhan CN, Savill J: Resolution of inflammation: the beginning programs the end. Nat Immunol 2005;6: 1191-1197. (Pubitemid 43045627)
110. Serhan CN: Novel chemical mediators in the resolution of inflammation: resolvins and protectins. Anesthesiol Clin 2006;24:341-364.
111. Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Petasis N, Serhan C, Van Dyke T: Resolvin E1 Regulates Inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol 2007;179:7021-7029.
112. Arita M, Clish CB, Serhan CN: The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem Biophys Res Commun 2005;338:149-157. (Pubitemid 41540550)